Determining drug dose in the era of targeted therapies: playing it (un)safe?

HIGHLIGHTS

• who: Sigrid S. Skånland from the DepartmentOslo University have published the research: Determining drug dose in the era of targeted therapies: playing it (un)safe?, in the Journal: (JOURNAL) of 15/07/2022
• what: The study showed that BTK occupancy, inhibition of BTK downstream signaling, and autophosphorylation (Tyr223), as well as reductions of plasma chemokine CCL3 and CCL4 levels, were similar at the three dose levels , indicating that the currently recommended dose is superfluously high if the effects of ibrutinib are on target. The phase II TIDAL trial was designed to compare continuous and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.